Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Journal of Virology
|
January 4, 2013
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine
Steven Rockman, Lorena E Brown, Ian G Barr, et al.
The Journal of Infectious Diseases
|
September 30, 2010
A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults
Kawsar R Talaat, Michael E Greenberg, Michael H Lai, et al.
Biotechnology and Bioengineering
|
February 12, 2025
Development of Methods to Produce SARS CoV-2 Virus-Like Particles at Scale
Melissa A Edeling, Linda Earnest, Julio Carrera Montoya, et al.
Ebiomedicine
|
July 19, 2016
What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins
Hillary A Vanderven, Fernanda Ana-Sosa-Batiz, Sinthujan Jegaskanda, et al.
Vaccine
|
June 21, 2023
Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine
Aleksei Ekimov, Arun B Arunachalam, Taylor Blake, et al.
Vaccine
|
September 6, 2016
Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial
William J H Mcbride, Walter P Abhayaratna, Ian Barr, et al.
JCI Insight
|
January 9, 2025
Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines
Wen Shi Lee, Kevin J Selva, Jennifer Audsley, et al.
EMBO Molecular Medicine
|
March 10, 2026
IFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination
Wuji Zhang, E Kaitlynn Allen, Shihan Li, et al.
NPJ Vaccines
|
January 17, 2026
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
Linda Earnest, Daniel Fernandez Ruiz, Melissa A Edeling, et al.
Science Translational Medicine
|
April 1, 2026
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses
Thi H O Nguyen, Isabelle J H Foo, Ruth A Purcell, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Journal of Virology
|
January 4, 2013
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine
Steven Rockman, Lorena E Brown, Ian G Barr, et al.
The Journal of Infectious Diseases
|
September 30, 2010
A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults
Kawsar R Talaat, Michael E Greenberg, Michael H Lai, et al.
Biotechnology and Bioengineering
|
February 12, 2025
Development of Methods to Produce SARS CoV-2 Virus-Like Particles at Scale
Melissa A Edeling, Linda Earnest, Julio Carrera Montoya, et al.
Ebiomedicine
|
July 19, 2016
What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins
Hillary A Vanderven, Fernanda Ana-Sosa-Batiz, Sinthujan Jegaskanda, et al.
Vaccine
|
June 21, 2023
Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine
Aleksei Ekimov, Arun B Arunachalam, Taylor Blake, et al.
Vaccine
|
September 6, 2016
Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial
William J H Mcbride, Walter P Abhayaratna, Ian Barr, et al.
JCI Insight
|
January 9, 2025
Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines
Wen Shi Lee, Kevin J Selva, Jennifer Audsley, et al.
EMBO Molecular Medicine
|
March 10, 2026
IFN-gene signatures in B cells following influenza A and B virus infection and influenza vaccination
Wuji Zhang, E Kaitlynn Allen, Shihan Li, et al.
NPJ Vaccines
|
January 17, 2026
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
Linda Earnest, Daniel Fernandez Ruiz, Melissa A Edeling, et al.
Science Translational Medicine
|
April 1, 2026
Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B viruses
Thi H O Nguyen, Isabelle J H Foo, Ruth A Purcell, et al.
Page
of 5